David Hanna is a senior counsel in the Life Sciences Group in the Litigation Department, where he focuses on biologic drug patent and Hatch-Waxman patent litigation. David’s biologics drug patent litigation experience includes litigating matters relating to Avastin® (bevacizumab) and Herceptin® (trastuzumab).

David has represented both patentees and generic filers in Hatch-Waxman litigation. He has litigated matters relating to Imbruvica® (ibrutinib), Xarelto® (rivaroxaban), Suboxone® (buprenorphine naloxone), Pradaxa® (dabigatran etexilate), Ultiva® (remifentanil hydrochloride), Daytrana® (methylphenidate), Dymista® (azelastine HCl/fluticasone propionate), Epaned® (enalapril maleate), and Brisdelle® (paroxetine).

David has also represented a major pharmaceutical company in product liability matters relating to Viread®, Truvada®, Atripla®, and other antiviral medications containing tenofovir disoproxil fumarate (“TDF”).

In the top law firm directory The Legal 500 US, a client recommended David, noting his client service for being “super responsive and very detail oriented.”